The Latest Cardiac and Vascular News
Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM […]
MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net […]
Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting […]
Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances […]
Baylis Medical Technologies to increase investment in radiology and neurosurgery business in Canada MISSISSAUGA, Ont. (October 6, 2021) – Baylis Medical Company Inc. is pleased to announce it has reached an agreement to sell its cardiology business to Boston Scientific Corporation. The acquisition, for an upfront payment of $1.75 billion […]
Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The data […]
Company to add mechanical thrombectomy platform to peripheral interventions portfolio MARLBOROUGH, Mass., Sept. 21, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve […]
Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolism MARLBOROUGH, Mass., Aug. 4, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the […]
MARLBOROUGH, Mass., July 27, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis and 52.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
PINNACLE FLX study meets 24-month endpoint, reinforces positive 12-month outcomes with next-generation device for patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., July 21, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial […]
